Compare NRG Energy Inc (NRG) vs TG Therapeutics Inc (TGTX) Price & Performance

NRG Energy trades at $107.97, down 0.59% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings of $1.49 per share, missing expectations of $1.69, though revenue growth remains positive with 2026 projections at $33.1 billion. Recent developments include a landmark 1.2 GW Texas data center power project and the acquisition of LS Power assets, positioning for growth in hyperscale computing demand.

The investment outlook is cautiously optimistic with strong analyst support (70% buy ratings) and a consensus price target of $202.90 offering significant upside. However, recent earnings misses, rising debt levels (56.42% debt-to-asset ratio in 2025), and execution risks on major capital projects present near-term challenges. The stock's valuation appears reasonable with P/E of 27.69 and P/S of 0.65 relative to sector peers.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.